A Dose Reduction Immunobridging and Safety Study of Two HPV Vaccines in Tanzanian Girls

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

930

Participants

Timeline

Start Date

February 23, 2017

Primary Completion Date

January 15, 2020

Study Completion Date

March 31, 2027

Conditions
Human Papilloma Virus
Interventions
DRUG

bivalent HPV vaccine

head to head comparisons of different dose schedules and HPV vaccine types

DRUG

nonavalent HPV vaccine

head to head comparisons of different dose schedules and HPV vaccine types

Trial Locations (1)

Unknown

Mwanza Intervention Trials Unit (MITU), Mwanza

All Listed Sponsors
collaborator

University of York

OTHER

collaborator

Institut Català d'Oncologia

OTHER

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Karolinska Institutet

OTHER

collaborator

Technische Universität Berlin

OTHER

collaborator

Tanzanian National Institute for Medical Research

UNKNOWN

collaborator

University of Glasgow

OTHER

lead

London School of Hygiene and Tropical Medicine

OTHER